Sort   by:  
 Page size 
UnknownSotrovimab therapy elicits antiviral activities against Omicron BQ.1.1 and XBB.1.5 in sera of immunocompromised patients.
Antibodies effective against the recent Omicron sublineages are missing. By taking advantage of a multi-centric prospective cohort of immunocompromised individuals treated for mild-to-moderate COVID-19, Bruel et al. show that administration of 500 mg of sotrovimab induces serum neutralization and an...
S-EPMC11232389 | biostudies-literature
UnknownLong Covid: a global health issue - a prospective, cohort study set in four continents.

Introduction

A proportion of people develop Long Covid after acute COVID-19, but with most studies concentrated in high-income countries (HICs), the global burden is largely unknown. Our study aims to characterise long-term COVID-19 sequelae in populations globally and compare the prevalence...
S-EPMC11552006 | biostudies-literature
Sort   by:  
 Page size